How Cannabinoid Signaling Works Throughout the Body: An Overview
The endocannabinoid system plays roles in numerous physiological processes including cardioprotection, but therapeutic development has been limited by psychoactive side effects and incomplete understanding of mechanisms.
Quick Facts
What This Study Found
This review provided a broad overview of the endocannabinoid system and its therapeutic potential, with particular attention to an emerging area: cardioprotection.
The endocannabinoid system is involved in a wide range of physiological processes, and several cannabinoids can be prescribed in Canada for conditions including nausea and pain. The review noted that beyond these established uses, an increasing number of reports suggest beneficial effects of endocannabinoid signaling for the cardiovascular system.
However, the therapeutic potential of cannabinoids remains largely unrealized for two reasons. First, the mechanisms through which cannabinoids produce their effects are not fully understood. Second, pronounced psychoactive side effects have limited clinical development.
The review covered the basic components of the endocannabinoid system, known physiological roles, and the range of disease conditions in which cannabinoid receptor signaling has been implicated.
Key Numbers
Several cannabinoids available by prescription in Canada for nausea and pain. The review covers multiple physiological systems but does not present original quantitative data.
How They Did This
Review article providing an overview of the endocannabinoid system, its physiological roles, and conditions where cannabinoid signaling has therapeutic implications, with emphasis on cardioprotection.
Why This Research Matters
This review contextualizes the therapeutic potential of cannabinoids within the broader understanding of the endocannabinoid system, highlighting both the promise and the obstacles to clinical translation.
The Bigger Picture
The cardioprotective potential of endocannabinoid signaling is a relatively new research direction that could expand cannabinoid medicine beyond its current applications in pain, nausea, and spasticity. Understanding how to harness these benefits without psychoactive effects remains the central challenge.
What This Study Doesn't Tell Us
Broad overview that does not deeply analyze any single application. The cardioprotective evidence is described as emerging rather than established. Published from a Canadian perspective, regulatory context may differ in other countries.
Questions This Raises
- ?Could peripheral-only cannabinoid compounds provide cardioprotection without psychoactive effects?
- ?Which cardiovascular conditions are most amenable to cannabinoid-based intervention?
- ?How does the endocannabinoid system interact with established cardiovascular medications?
Trust & Context
- Key Stat:
- Emerging evidence suggests endocannabinoid signaling provides cardioprotection
- Evidence Grade:
- Broad review of the endocannabinoid system. Moderate because it synthesizes established knowledge with emerging evidence.
- Study Age:
- Published in 2017.
- Original Title:
- Cannabinoid signaling in health and disease.
- Published In:
- Canadian journal of physiology and pharmacology, 95(4), 311-327 (2017)
- Authors:
- Lu, Yan, Anderson, Hope D
- Database ID:
- RTHC-01440
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does the endocannabinoid system do?
It is involved in numerous physiological processes including pain modulation, appetite, mood, and potentially heart protection. It consists of receptors (CB1, CB2), endocannabinoids (anandamide, 2-AG), and enzymes that create and break down these signaling molecules.
Why aren't more cannabinoid medicines available?
Two main barriers: the psychoactive side effects of compounds that activate CB1 receptors in the brain, and incomplete understanding of how the system works, making it difficult to develop targeted treatments.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01440APA
Lu, Yan; Anderson, Hope D. (2017). Cannabinoid signaling in health and disease.. Canadian journal of physiology and pharmacology, 95(4), 311-327. https://doi.org/10.1139/cjpp-2016-0346
MLA
Lu, Yan, et al. "Cannabinoid signaling in health and disease.." Canadian journal of physiology and pharmacology, 2017. https://doi.org/10.1139/cjpp-2016-0346
RethinkTHC
RethinkTHC Research Database. "Cannabinoid signaling in health and disease." RTHC-01440. Retrieved from https://rethinkthc.com/research/lu-2017-cannabinoid-signaling-in-health
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.